STOCK TITAN

Gracell Biotechnologies Announces Senior Management Team Share Purchase Plan

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Gracell Biotechnologies (NASDAQ: GRCL) announced that its senior management, including CEO Dr. William Cao, CFO Dr. Yili Kevin Xie, and CMO Dr. Martina A. Sersch, plan to purchase up to $2 million of the company's American depositary shares (ADSs) over the next three months. This move indicates confidence in the company's future, as the management team opts to invest their personal funds in the company's stock. Gracell is focused on developing affordable cell therapies for cancer treatment, leveraging innovative technology platforms.

Positive
  • Management team plans to purchase up to $2 million worth of company ADSs, indicating leadership confidence.
  • Commitment from senior management to invest personally may boost investor sentiment.
Negative
  • None.

SUZHOU, China and PALO ALTO, Calif., Nov. 23, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that members of its senior management team, including its Chairman of Board and Chief Executive Officer Dr. William (Wei) Cao, Chief Financial Officer Dr. Yili Kevin Xie and Chief Medical Officer Dr. Martina A. Sersch, have informed the Company of their intention to use their personal funds to purchase the Company's American depositary shares ("ADSs") on the open market for an aggregate amount up to a maximum of $2 million within the next three months.

About Gracell

Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR, TruUCAR and SMART CARTTM technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com.Follow @GracellBio on LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing date of the offering. The words "anticipate," "look forward to," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the section entitled "Risk Factors" in Gracell's most recent annual report on Form 20-F as well as discussions of potential risks, uncertainties, and other important factors in Gracell's subsequent filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Gracell specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Readers should not rely upon the information on this page as current or accurate after its publication date.

Media contact
Marvin Tang
marvin.tang@gracellbio.com

Investor contact
Gracie Tong
gracie.tong@gracellbio.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/gracell-biotechnologies-announces-senior-management-team-share-purchase-plan-301430891.html

SOURCE Gracell Biotechnologies Inc.

FAQ

What is the recent announcement from Gracell Biotechnologies regarding management share purchases?

Gracell's senior management announced plans to purchase up to $2 million in the company's ADSs over the next three months.

How much will Gracell management invest in their own shares?

The management team plans to invest up to $2 million in Gracell's American depositary shares.

Who from Gracell's management team is purchasing shares?

CEO Dr. William Cao, CFO Dr. Yili Kevin Xie, and CMO Dr. Martina A. Sersch are among those making the purchases.

What does the share purchase by Gracell's management signify for investors?

The share purchase may indicate confidence in the company's future performance and could positively influence investor sentiment.

When do Gracell's management team plans to execute their share purchases?

The management team intends to complete the share purchases within the next three months.

Gracell Biotechnologies Inc.

NASDAQ:GRCL

GRCL Rankings

GRCL Latest News

GRCL Stock Data

989.87M
71.55M
16.39%
63.11%
1.23%
Biotechnology
Healthcare
Link
China
Suzhou